Spastic paraplegia in 'dominant optic atrophy plus' phenotype due to OPA1 mutation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Super-Refractory Status Epilepticus (SRSE) in a Patient With Compound Heterozygous OPA1 Variants: Case Report and Literature Review.Annals of clinical and translational neurology · 2026
   Review
2. OPA1 Deficiency Impairs NGF Signaling and Drives Sympathetic Neurodegeneration.JACC. Basic to translational science · 2026
   Article
3. Dystonia, spastic tetraplegia, and ataxia due to a novel mutation in the dynamin domain of OPA1.Annals of clinical and translational neurology · 2024
   Article
4. Mutation spectrum of the OPA1 gene in a large cohort of patients with suspected dominant optic atrophy: Identification and classification of 48 novel variants.PloS one · 2021
   Article
5. Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis.Brain : a journal of neurology · 2015
   Review
6. Disturbed mitochondrial dynamics and neurodegenerative disorders.Nature reviews. Neurology · 2015
   Review
7. 'Behr syndrome' with OPA1 compound heterozygote mutations.Brain : a journal of neurology · 2015
   Article
8. The optic nerve: a "mito-window" on mitochondrial neurodegeneration.Molecular and cellular neurosciences · 2013
   Review
9. Dominant optic atrophy.Orphanet journal of rare diseases · 2012
   Review
10. Reply: Spastic paraplegia in ‘dominant optic atrophy plus’ phenotype due to OPA1 mutation.Brain : a journal of neurology · 2011
    Article
11. Clinical variability in hereditary optic neuropathies: Two novel mutations in two patients with dominant optic atrophy and Wolfram syndrome.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
    Article

Corrections and comments

• Commented on by
  Reply: Spastic paraplegia in ‘dominant optic atrophy plus’ phenotype due to OPA1 mutation.2011
• Comment on
  Multi-system neurological disease is common in patients with OPA1 mutations.2010
• Comment on
  Heterozygous OPA1 mutations in Behr syndrome.2011

Authors and funding

6 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as